Reuters logo
BRIEF-FDA grants orphan drug status to Cellect's Apograft for acute GVHD and chronic GVHD
September 5, 2017 / 11:27 AM / in 2 months

BRIEF-FDA grants orphan drug status to Cellect's Apograft for acute GVHD and chronic GVHD

Sept 5 (Reuters) - Cellect Biotechnology Ltd

* FDA grants orphan drug status to Cellect’s Apograft for acute GVHD and chronic GVHD

* ‍FDA granted orphan drug designation for Apograft for prevention of acute and chronic GVHD in transplant patients​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below